Introduction
Materials and methods
Search strategy
Selection of eligible articles
Inclusion and exclusion criteria
Data extraction
Study design
Patient characteristics
Imaging techniques
Image evaluation
Reference standard
Time interval between CT and reference standard
Data on resectability/unresectability
Data-analysis
Publication bias
Summary positive predictive value
Exploratory analysis
Subgroup analysis
Results
Search strategy and selection of eligible articles
Study design
Study author | Year of publication/Journal | Study period | Country of origin* | Type of study† | Department first author | Type of data collection | Ethical approval |
---|---|---|---|---|---|---|---|
Ellsmere [18] | 2005/Surg Endosc | Jan 1999-March 2002 | USA | Multi-centre | Surgery | Retrospective | UNCLEAR |
Imbriaco [19] | 2005/AJR Am J Roentgenol | Sept 2001-Feb 2003 | Italy | Multi-centre | Radiology | Prospective | YES (informed consent) |
Karmazanovsky [20] | 2005/Abdom Imaging | 1994-2003 | Russia | Single-centre | Radiology | Retrospective | UNCLEAR |
Li [21] | 2005/J Comput Assist Tomogr | Dec 2001-Feb 2004 | China | Single-centre | Radiology | Retrospective | UNCLEAR |
Phoa [22] | 2005/J Surg Oncol | Feb 1997-Jul 1999 | The Netherlands | Single-centre | Radiology | Prospective study (retrospective evaluation) | UNCLEAR |
Imbriaco [23] | 2006/Radiol Med | Sept 2001-March 2004 | Italy | Single-centre | Radiology | Unclear | UNCLEAR |
Tamm [24] | 2006/Abdom Imaging | Not available | USA | Single-centre | Radiology | Retrospective | YES |
Kala [25] | 2007/Eur J Radiol | Not available | Czech Republic | Multi-centre | Surgery | Retrospective | UNCLEAR |
Olivie [26] | 2007/JOP | Feb 2003-Jun 2004 | Canada | Multi-centre | Radiology | Prospective | YES (informed consent) |
Smith [27] | 2007/Pancreas | March 2002-March 2005 | UK | Single-centre | Radiology | Retrospective | UNCLEAR |
Zamboni [28] | 2007/Radiology | March 2003-March 2006 | USA | Single-centre | Radiology | Retrospective | YES |
Furukawa [29] | 2008/Arch Surg | Sept 2002-March 2005 | Japan | Single-centre | Radiology | Prospective | YES |
Klauss [30] | 2008/Pancreatology | March 2005-Aug 2006 | Germany | Multi-centre | Radiology | Prospective (retrospective evaluation) | YES (informed consent) |
Shah [31] | 2008/J Surg Res | NA | USA | Single-centre | Surgery | Retrospective | YES |
Manak [32] | 2009/Abdom Imaging | Jan 2000-Jul 2005 | Germany | Multicentre | Radiology | Retrospective | UNCLEAR |
Park [33] | 2009/J Magn Reson Imaging | Jan 2004-Jul 2008 | Korea | Multi-centre | Radiology | Retrospective | YES |
Satoi [34] | 2009/Hepatogastroenterology | Jan 2000-Apr 2005 | Japan | Single-centre | Surgery | Retrospective | YES (informed consent) |
Croome [35] | 2010/Can J Surg | Jan 2005-Dec 2006 | Canada | Multi-centre | Surgery | Retrospective | YES |
Grieser [36] | 2010/Acta Radiologica | Jan 2002- Jan 2007 | Germany | Single-centre | Radiology | Retrospective | YES |
Grossjohann [37] | 2010/Scand J Gastroenterology | Dec 2005-Dec 2007 | Denmark | Multi-centre | Radiology | Prospective (retrospective evaluation) | YES |
Kaneko [38] | 2010/J Comput Assist Tomogr | Jan 2000-March 2009 | USA | Multi-centre | Radiology | Retrospective | YES |
Lee [39] | 2010/Eur J Radiol | Jan 2003- Jun 2005 | Korea | Multi-centre | Radiology | Retrospective | UNCLEAR |
Koelblinger [40] | 2011/Radiology | Sept 2006-Nov 2007 | Austria | Multi-centre | Radiology | Prospective (IC) | YES |
Fang [41] | 2012/Pancreatology | Nov 2008-Aug 2010 | China | Multi-centre | Surgery | Prospective (retrospective evaluation) | YES |
Khattab [42] | 2012/The Egyptian Journal of Radiology and Nuclear Medicine | Dec 2009-Aug 2011 | Egypt | Single-centre | Radiology | Prospective (IC) | YES |
Yao [43] | 2012/ANZ J Surg | Dec 2006-Jul 2009 | Australia | Multi-centre | Surgery | Retrospective | UNCLEAR |
Cieslak [44] | 2014/Pancreatology | Jan 2007-Dec 2010 | The Netherlands | Multi-centre | Gastroenterology | Retrospective | UNCLEAR |
Hassanen [45] | 2014/The Egyptian Journal of Radiology and Nuclear Medicine | Oct 2010-March 2013 | Egypt | Single-centre | Radiology | Prospective (IC) | YES |
Iscanli [46] | 2014/Turk J Gastroenterol | NA | Turkey | Single-centre | Radiology | Retrospective | YES |
Patient characteristics
Study author | Patient Population (suspected or known) | Selection criteria (inclusion and/or exclusion criteria) | Number of total patients included* | Distribution of patients (adenocarcinoma; other malignancies; benign lesion) | Age (mean or median and SD or range) in years | Sex ratio (male: female) | Consecutive or random selection |
---|---|---|---|---|---|---|---|
Ellsmere [18] | Known | Inclusion: Patients with a diagnosis of pancreatic head adenocarcinoma who underwent a gastrointestinal procedure. Exclusion: Patients who did not undergo a thin-section dual-phase MDCT and attempted pancreaticoduodenectomy at the institution | 44 | Adenocarcinoma: 44 | Not available | Not available | YES |
Imbriaco [19] | Suspected | Inclusion: Patients with a suspected pancreatic mass based on clinical symptoms, laboratory findings, and results of ERCP or sonography | 71 | Adenocarcinoma: 37 Other malignancy: 3 Benign lesions: 31 | Mean: 63 ± 12 Range:29-80 | 41:30 | YES |
Karmazanovsky [20] | Known | Inclusion: Patients who had morphologically confirmed pancreatic head adenocarcinoma by using spiral CT with bolus intravenous contrast enhancement; Only patients who underwent intraoperative surgical exploration were included in this investigation. | 89 | Adenocarcinoma:89 | Mean: 60 Range: 23-80 | 52:37 | UNCLEAR |
Li [21] | Suspected | Inclusion: Patients with presumed pancreatic cancer underwent surgery | 54 | Adenocarcinoma: 54 | Mean: 61.2 Range: 40-79 | 37:17 | YES |
Phoa [22] | Suspected | Inclusion: Patients suspected of having pancreatic carcinoma who underwent a spiral CT for staging; Patients with pancreatic head carcinoma eventually who underwent surgery for attempted resection with curative intent. Exclusion: patients with cholangiocarcinomas, cystic tumours or endocrine tumours. | 71 | Adenocarcinoma: 71 | Median: 62 Range: 42-76 | 33:38 | YES |
Imbriaco [23] | Suspected | Patients with suspected pancreatic cancer based on clinical and laboratory findings and on results of endoscopic retrograde cholangiopancreatogram (ERCP) or ultrasonography (US). | 78 | Adenocarcinoma:46 Benign lesions: 32 | Mean ± SD: 64 ± 12 | 42:36 | UNCLEAR |
Tamm [24] | Known | Inclusion: Patient with biopsy-proven adenocarcinoma of the pancreas who underwent MDCT imaging using a dual-phase pancreas protocol and endoscopic ultrasound. Exclusion: patients with other histology or who underwent CT scanning using other imaging regimens were not included. Also excluded were patients who were identified as having resectable disease but refused surgery, were lost to follow-up or had significant comorbid disease that precluded surgery. | 55 | Adenocarcinoma: 55 | Mean: 67 Range: 46–86 | 31:24 | UNCLEAR |
Kala [25] | Known | Inclusion: Patients with pancreatic cancer. | 55 (undergoing CT) | Adenocarcinoma: 55 | Not available | Not available | UNCLEAR |
Olivie [26] | Suspected or known | Inclusion: Patients referred with a known or suspected diagnosis of cancer of the head and patients found to be resectable. | 28 (study group) | Adenocarcinoma:28 (study group) | Mean: 63 Range: 40-76 | 14:14 | YES |
Smith [27] | Known | Inclusion: Patients with pancreatic ductal adenocarcinoma. Exclusion: Patients with ampullary tumours, tumours of the body and tail of the pancreas, and benign disease | 33 (underwent surgery) | Adenocarcinoma: 33 (study group) | Mean: 67.2 Range: 28- 88 (33 patients) | 20:13 (33 patients) | YES |
Zamboni [28] | Known | Inclusion: Patients who underwent surgical staging or attempt at curative resection for pancreatic carcinoma at our institution; Patients who underwent scanning in our institution with multiphase multidetector CT with multiplanar reconstructions and two- and three-dimensional CT angiography. Exclusion: all patients who underwent scanning at other institutions or with different CT protocols. | 114 | Adenocarcinoma: 110 Other malignancies: 4 | Mean:65.9 Range: 33-85 | 52: 62 | UNCLEAR |
Furukawa [29] | Known | Inclusion: Patients were referred for treatment of invasive ductal carcinoma of the pancreas. Exclusion: patients with other histologic types of pancreatic tumour such as endocrine tumour, intraductal papillary mucinous tumour, and solid and pseudopapillary tumour. Patients who already received surgical or medical treatment at another hospital. | 213 | Adenocarcinoma: 213 | Mean: 64 Range: 32-82 | 136: 77 | YES |
Klauss [30] | Suspected | Inclusion: Patients with strong clinical suspicion of pancreatic carcinoma based on icterus, a preceding CT or ultrasound scan, unspecific weight loss, or an elevated CA19-9. Exclusion: Patients with renal impairment with creatinine values 12 mg/dL, manifest hyperthyroidism, known contrast medium allergy, and failure to consent to the study. | 80 | Adenocarcinoma: 36 Other malignancy: 9 Benign lesions: 35 | Mean: 64.9 Range: 37–89 | 43:37 | UNCLEAR |
Shah [31] | Known | Inclusion: Patients with pancreatic adenocarcinoma Exclusion: Patients presented with other pancreatic neoplasms, such as ampullary adenocarcinoma, pancreatic endocrine tumours, or cystic neoplasms. | 88 | Adenocarcinoma: 88 | Not available | Not available | YES |
Manak [32] | Known | Inclusion: Patients with pathologically proven pancreatic adenocarcinoma underwent MDCT and who underwent surgery. Excluded: Patients who received a course of radio-chemotherapy before surgery. | 48 | Adenocarcinoma: 48 | Mean: 64.7 Range: 43–89 | 26:22 | UNCLEAR |
Park [33] | Known | Inclusion: Patients with pancreatic cancer who had undergone curative or palliative surgery; Patients with both preoperative contrast-enhanced MRI including MRCP and triple phase MDCT within a month before surgery; Patients with diagnosed pancreatic ductal carcinoma on pathology examination of a surgical specimen. | 54 | Adenocarcinoma: 54 | Mean: 63.1 Range: 28–83 | 32:22 | UNCLEAR |
Satoi [34] | Known | Inclusion: Patients with ductal adenocarcinoma after clinical; diagnosis of pancreatic cancer using ultrasonography, CT, MRCP, ERCP, endoscopic ultrasonography, cytological examination of the bile juice and/or biopsy of the bile duct mucosa. Exclusion: endocrine tumour of the pancreas, intraductal papillary mucinous cancer, acinar cell carcinoma, or anaplastic cancer. | 80 (patients undergoing multislice CT) | Adenocarcinoma: 80 | Mean: 65 Range 39-83 | 37:43 | YES |
Croome [35] | Suspected | Inclusion: Patients referred to pancreatic surgeons because of suspected cancer of the pancreatic head. | 96 (undergoing CT) | Not available | Not available | Not available | UNCLEAR |
Grieser [36] | Known | Inclusion: Patients who underwent surgical exploration or resection of a pancreatic mass at our medical center; patients who underwent a preoperative triphasic MDCT examination (4–64-slice MDCT) performed at our clinic; a detailed report of the operation and a histopathological analysis available. | 105 | Adenocarcinoma: 60 Other malignancies: 10 Benign lesions: 35 | Mean ± SD: 58 ± 15 | 73:32 | YES |
Grossjohann [37] | Known/suspected | Inclusion: patients with pancreatic head tumours and with suspected pancreatic head tumours. | 49 | Adenocarcinoma: 44 Benign lesions: 5 | Mean: 66 years Range: 42–83 | 26:23 | YES |
Kaneko [38] | Known | Inclusion: Patients presenting to our institution with adenocarcinoma of the pancreatic head were included. Exclusion: located in the pancreatic body or tail were excluded, as well as all patients with other neoplastic/inflammatory processes of the pancreas. | 109 (underwent surgery) | Adenocarcinoma: 109 | Mean: 65.1 Range: 39-86 | 56:53 | YES |
Lee [39] | Known | Inclusion: Patients with newly diagnosed pancreatic ductal adenocarcinoma and who underwent surgery. | 56 | Adenocarcinoma: 56 | Mean: 60.9 Range: 37-76 | 30: 26 | UNCLEAR |
Koelblinger [40] | Suspected | Inclusion: Patients suspected of having pancreatic cancer referred to hepatobiliary-pancreatic surgeons; suspected of having pancreatic cancer on the basis of findings from clinical examination (e.g., jaundice, increased CA 19-9 levels, rapid weight loss or previous US or CT studies performed). | 89 | Adenocarcinoma: 43 Other malignancies: 8 Benign lesions: 38 | Mean ± SD: 65.5 ± 10.7 | 41:48 | YES |
Fang [41] | Diagnosed | Inclusion: Patients with confirmed pancreatic and periampullary neoplasms. | 80 | Adenocarcinoma: 57 Other malignancy: 23 | Mean ± SD: 57.9 ± 1.7 Range: 15-91 | 49:31 | UNCLEAR |
Khattab [42] | Suspected | Inclusion: Patients with clinical and sonographic findings that raised suspicions of pancreatic cancer were included in our study. | 39 | Adenocarcinoma: 39 | Mean: 58.3 Range: 44-73 | 29:10 | UNCLEAR |
Yao [43] | Known | Inclusion: Patients with potentially resectable pancreatic tumours detected on contrasted CT imaging and who also had preoperative PET/CT scans. | 36 | Adenocarcinoma: 30 Other malignancies: 3 Benign lesions: 4 1 patient had both adenocarcinoma and other malignancy | Median: 71 Range: 32–84 | 24:12 | UNCLEAR |
Cieslak [44] | Suspected | Inclusion: Patient who underwent exploratory laparotomy for a suspected pancreatic or periampullary malignancy; Patients who underwent both preoperative contrast enhanced CT and endoscopic ultrasonography. | 86 | Adenocarcinoma: 37† Other malignancy: 30† Benign lesions: 9† | Mean ± SD: 65 ± 10.5 | 49:37 | YES |
Hassanen [45] | Suspected | Inclusion: patients with suspected pancreatic carcinoma underwent biphasic MDCT for pancreatic examination. | 47 (study group) | Adenocarcinoma: 47 | Mean: 63.5 Range: 45-82 | 32:15 | YES |
Iscanli [46] | Known | Inclusion: Patients with pancreatic adenocarcinoma confirmed by surgery-pathology or clinical follow-up. | 124 | Adenocarcinoma: 124 | Mean: 60.2 Range: 28-84 | 83: 41 | YES |
CT technical features
Study author | Type of scanner | Bowel preparation | Intravenous contrast agent | Phases | Execution described in detail* |
---|---|---|---|---|---|
Ellsmere [18] | Not available | Not available | 100–150-mL Ultravist | Pancreatic phase: 40-s post-contrast delay, reconstruction slice thickness 3 mm. Portal venous phase: 70-s post-contrast delay, reconstruction slice thickness 5 mm. | NO |
Imbriaco [19] | 4-slice | 10-15 min before CT exam: 500 mL water orally | 150 mL Ultravist 370 (Iopromide) | Portal venous phase: 60-s post-contrast delay, 1.25-mm reconstruction interval | YES |
Karmazanovsky [20] | Single-slice | Not available | 100 mL |
Bolus contrast enhancement
Arterial phase: 25-s delay Portal vein phase: 80-s delay | NO |
Li [21] | 4-slice | Not available | 120 mL Ultravist 350 (Iopromide) | Arterial phase: 20-s post-contrast delay, 2.5 mm collimation Pancreatic phase: 45-s post-contrast delay, 2.5 mm collimation Hepatic phase: 80-s post-contrast delay, 2.5 mm collimation | YES |
Phoa [22] | 2-slice | Not available | 130 mL Omnipaque 300 | Pancreatic phase: 50-s post-contrast delay, collimation 2.5 mm | NO |
Imbriaco [23] | 4-slice | 500 mL water orally | 150 mL (370 mg I/mL) | Portal venous phase: 60-s post-contrast delay, reconstruction interval 1.25 mm | YES |
Tamm [24] | 4-slice | Not available | 150 mL Optiray 300 (Ioversol) | Pancreatic phase: 25-s post-contrast delay, 2.5 mm slice thickness and reconstruction to 1.25 mm contiguous images. Portal phase: 55-s post-contrast delay, 5 mm slice thickness and reconstruction to 2.5 mm contiguous images. | YES |
Kala [25] | single-slice | Not available | 125 mL Optiray 350 | Not available | NO |
Olivie [26] | 16-slice | 500 mL of water orally | 150 mL Omnipaque 350 | Arterial phase: 20-s post-contrast delay, section on width of 2.5 mm and an interval reconstruction of 1.25 mm. Late arterial phase: 40-s post-contrast delay, section on width of 2.5 mm and an interval reconstruction of 1.25 mm Portal phase: 60-s post-contrast delay, section on width of 2.5 mm and an interval reconstruction of 1.25 mm | YES |
Smith [27] | 4- or 8-slice | Not available | 100 mL Omnipaque 300 | Pancreatic phase: 40-s post-contrast delay, collimation 2.5 mm; reconstruction overlap, 1.25 mm Portal-venous phase: 65-s post-contrast delay, collimation 2.5 mm, reconstruction overlap 1.25 mm | YES |
Zamboni [28] | 4-, 8-, 16-, 64- slice | Not available | 150–200 mL Optiray 350 (Ioversol) |
Bolus tracking
: 150-HU threshold of enhancement abdominal aorta at the origin of the celiac axis Late arterial–early portal venous phase: 15- s post-threshold delay, collimation 1.25 mm for 4- and 8-slice CT, 0.625 mm for 16-slice or 0.5 mm for 64-slice CT. Venous phase: 25-s after arterial phase, collimation 1.25 mm for 4- and 8-slice CT, 0.625 mm for 16-slice, or 0.5 mm for 64-slice CT. | YES |
Furukawa [29] | 16-slice | Not available | 150 mL Iopamiron (Iopamidol) | Early arterial phase: 20-s post-contrast delay Late arterial phase: 40-s post-contrast delay Pancreatic phase: 70-s post-contrast delay Delayed phase: 120-s post-contrast delay 1-mm section thickness and reconstructed at 1-mm intervals (0.5-mm overlap) | YES |
Klauss [30] | 16-slice | 1.5 L still water | 120 mL Ultravist 370 |
Bolus threshold
: 100-HU enhancement in the aorta at the level of the superior mesentery artery Arterial phase: 8-s post-threshold delay, reconstructed slice thickness 2/1 Portal venous phase: 35-s post-threshold delay, reconstructed slice thickness (3/3 first and 1/0.5 s) | YES |
Shah [31] | 64-slice | Water | Intravenous contrast (type/concentration not available | Arterial phase Pancreatic phase Hepatic venous phase | NO |
Manak [32] | 4- and 16-slice | 800 mL water orally with 40 mg butylscopolamin or 1 mg glucagon | 120 mL (300–370 mg iodine/mL) | Pancreatic phase: 35-s post-contrast delay, section thickness 3.0 mm Portal venous phase: 70-s post-contrast delay, section thickness 3.0 mm | YES |
Park [33] | 4-, 8-, 16-, and 64- slice | Not available | 120 mL Ultravist 370 (Iopromide) |
Bolus tracking
: 100 HU at abdominal aorta 64-slice/16-slice/8-slice Early arterial phase: 6-s post-threshold (23-s post-contrast delay), slice thickness 3 mm. Late arterial phase: 5–9-s interscan delay between early and late phases, (37-45-s post-contrast delay); slice thickness of 3 mm. Venous phase: 70-s post-threshold: slice thickness of 3 mm 4-slice Early arterial phase: 6-s post-threshold (23-s post-contrast delay), slice thickness of 3.2 mm. Late arterial phase: 5–9-s interscan delay between early and late phases, (37-45-s post-contrast delay); slice thickness of 3.2 mm. Venous phase: 70-s post-threshold: slice thickness of 3.2 mm. | YES |
Satoi [34] | 4-slice | Not available | Not available | Arterial and portal phase; slice thickness 1.25 mm | NO |
Croome [35] | Not available | Not available | Not available | Not available | NO |
Grieser [36] | 4-, 8-, 16-, and 64-slice | Not available | 100 mL Ultravist 370 (Iopromide) | Bolus threshold: aortic enhancement above 100 HU Early arterial phase: 4-s post-threshold delay (20-s post-contrast delay) Early portal venous phase: 20 s delay from the beginning of the arterial phase (40-s post-contrast delay) Venous phase: 60-s delay from the beginning of the arterial phase (80-s post-contrast delay) | YES |
Grossjohann [37] | 64-slice | Not available | Not available | Not available | NO |
Kaneko [38] | 4-, 16-, and 64-slice | Not available | 120–150 mL Omnipaque 350 | 4-slice Pancreas phase delay: 45 s, Slice thickness 1.25 mm, Portal venous phase: 60-70s, Slice thickness 1.25 mm, 16 and 64 slice Pancreatic phase: bolus tracking with trigger at 150 HU; slice thickness: 0.75 mm Portal venous phase: 10-s delay after pancreatic phase, slice thickness: 0.75 mm | YES |
Lee [39] | 4-slice | No oral contrast agent | 150 mL Ultravist 370 (Iopromide) |
Bolus triggering
: 100-HU enhancement of the descending aorta Arterial phase: 5-s post-threshold delay; reconstruction interval of 5 mm Portal venous phase: 72-s post-contrast delay; reconstruction interval of 5 mm | YES |
Koelblinger [40] | 64–slice | 20 min before CT exam: 1000 mL water orally | 150 mL Iomeron 300 (Iomeprol) |
Bolus triggering
: threshold of 100 HU in the abdominal aorta. Pancreatic parenchymal: 25 –s post-threshold, slice thickness 3 mm Portal venous phase: 23-s after pancreatic phase, section thickness 3 mm | YES |
Fang [41] | 64 slice | Not available | 80-100 mL Iopamiron |
Bolus tracking: 100 HU in the diaphragmatic section of the abdominal aorta Arterial-phase: 8-s post-threshold slice thickness 0.67 mm Portal venous phase: 60-s post-threshold; slice thickness 0.67 mm | YES |
Khattab [42] | 64-slice | 1000 mL of mixed water and contrast orally | 100 mL Omnipaque 350 |
Bolus triggering
: 110 HU in the aorta at corresponding level of superior mesenteric artery. Pancreatic arterial phase: 20-s post-threshold delay; section width of 1.5 mm Delayed venous phase: 50-s post-threshold delay; section width of 1.5 mm | YES |
Yao [43] | Not available | Not available | Not available | Not available | NO |
Cieslak [44] | Range: 16–64-slice | Oral contrast | 100-150 mL | Portal OR Arterial and portal; 5.0-mm slice thickness | NO |
Hassanen [45] | 16-slice | 600–800 mL water or water soluble contrast agent orally | 100 mL Ultravist 370 (Iopromide) |
Bolus triggering
: 110 HU in the abdominal aorta at the level of the celiac axis Late arterial phase: 10- s post-threshold delay; 3.0 mm Portal venous phase: 35-s post-threshold delay; 3.0 mm | YES |
Iscanli [46] | 16- or 64- slice | 1000 mL water orally | 90-110 mL Visipaque 320 (Iodixanol) or Ultravist 370 (Iopromide) |
Bolus tracking: 180-HU enhancement on the proximal abdominal aorta Arterial phase: start automatically when maximum contrast reached Pancreatic phase: 45-s post-contrast delay: slice thickness: 1-1.25 mm, Portal phase: 65-s post-contrast delay: slice thickness: 1-1.25 mm | YES |
Interpretation of CT
Study author | Method of reconstruction* | Observers (number and experience) | CT criteria for resectability or unresectability | Interpretation described in detail† | Blinded interpretation of CT‡ | Criteria defined§ |
---|---|---|---|---|---|---|
Ellsmere [18] | Not available | 4 abdominal radiologists independently | Criteria for resectability: 1. No distant metastasis; 2. A patent portal vein; 3. <50% arterial involvement | NO | YES | YES |
Imbriaco [19] | VR | 2 experienced abdominal radiologists independently | Criteria for unresectability: 1. Peripancreatic vascular invasion (defined as encasement of the celiac, hepatic, or superior mesenteric arteries or the portal or superior mesenteric vein) ¶; 2. Extrapancreatic invasion of adjacent tissues and organs other than duodenum; 3. Presence of hematogenous or distant lymph node metastases (other than peripancreatic nodes); 4. Signs of peritoneal carcinomatosis; 5. Distant lymph node exceeding 1.5 cm ¶ A vessel was considered to be involved if it showed a focal reduction in caliber, circumferential (>180°) encasement by tumour, or frank thrombosis. Involvement of the splenic artery or veins was not considered an absolute contraindication to resection unless the tumour extended into the splenoportal confluence or involved other splanchnic vessels. | NO | YES | YES |
Karmazanovsky [20] | MPR and VR | Not available | Criteria for unresectability: 1. Invasion of any of the vascular structures (portal vein, superior mesenteric vein, and artery) 2. Liver metastasis | NO | UNCLEAR | YES |
Li [21] | MPR and MIP and VR | 2 observers in consensus (10 and 5 years of experience in pancreatic imaging) | Criteria for unresectability: 1. Vascular invasion; 2. Hepatic metastasis 3. Other metastatic signs. | YES | YES | YES |
Phoa [22] | Not available | 2 experienced abdominal radiologists independently, followed by consensus | Criteria for unresectability: 1. Tumour infiltration was present; 2. If any vessel (portal or superior mesenteric vein, hepatic artery, and the superior mesenteric artery) showed involvement of >180 degrees; 3. If tumour convexity was scored as Loyer grade D or E ¶ 4. Liver metastases; 5. Distant lymph nodes larger than 1 cm ¶ Vascular invasion according to Loyer grade 1
Grade A: fat plane visible between tumour and vessel; Grade B: normal pancreatic tissue between tumour and vessel; Grade C: tumour adjacent to vessel with a contour convex towards the vessel; Grade D: tumour adjacent to vessel with a contour concave towards the vessel, Grade E: circumferential involvement of vessel; Grade F: thrombosis or occlusion of vessel. | NO | YES | YES |
Imbriaco [23] | Not available | 2 experienced radiologists independently | Criteria for unresectability: 1. Peripancreatic vascular invasion (defined as infiltration of the coeliac trunk, hepatic artery, superior mesenteric artery or portal vein, and superior mesenteric vein) ¶; 2. Extrapancreatic invasion of adjacent tissues 3. Hematogenous or lymph node metastasis (>1.5 cm) or peritoneal carcinomatosis. ¶ The vessel was considered involved when its circumference was reduced more than >180° by the tumour or by evident thrombosis. Involvement of the splenic artery or vein was not considered an absolute contraindication to surgery unless the tumour extended to splenic-mesenteric-portal confluence. | NO | YES | YES |
Tamm [24] | Not available | 3 abdominal radiologists independently | Criteria for unresectability: 1. Primary tumour involving the superior mesenteric or celiac arteries, involvement of the common hepatic artery, M1 disease, or occlusion of the superior mesenteric vein and/or portal vein. | NO | YES | YES |
Kala [25] | Not available | Not available | Criteria for unresectablity: 1. Tumour invasion to coeliac trunk, to common hepatic artery, superior mesenteric artery, superior mesenteric vein, portal vein, inferior caval vein, and aorta. | NO | UNCLEAR | Yes |
Olivie [26] | MPR and curved MPR | Not available | Criteria for unresectability: 1. Liver metastases; 2. Peritoneal carcinomatosis; 3. Tumour infiltration in contact with more than 180° of the circumference of the walls of major arteries (celiac trunk, hepatic artery, superior mesenteric artery) and involvement of more than 180° of the circumference of the portal vein or the superior mesenteric vein. | NO | YES | YES |
Smith [27] | MPR and MIP and VR | 2 radiologist independently followed by consensus | Criteria for unresectability: 1. Metastases 2. Vascular encasement: Lu grade 3 or 4¶ 3. Vascular occlusion 4. Direct invasion of bowel, spleen, and mesentery (duodenum excluded) 5. Lymphadenopathy (nodes > 1 cm in short axis) outside the peripancreatic chain. ¶ Vascular involvement (for the superior mesenteric vessels, coeliac artery, and portal vein) was estimated using the Lu grade 2. Grade 0: no contiguity of tumour to vessel; Grade 1: tumour contiguous less than one quarter of circumference; Grade 2: between one quarter and one half; Grade 3: between one half and three quarters; Grade 4: greater than three quarters. | NO | UNCLEAR | YES |
Zamboni [28] (initial clinical evaluation) | MPR and MIP and VR | 2 readers: one radiology resident/abdominal fellow (pool of 30 readers, with 2–6 years of experience) and one abdominal radiologist (pool of eight readers, with 8–20 years of experience). | Criteria for unresectability: 1. Distant disease (hepatic metastases, distant lymph node metastases, peritoneal metastases), 2. Invasion of adjacent organs other than the duodenum 3. Major vascular invasion: Grade 2, 3, or 4¶ 4. Lymph nodes were considered metastatic if the short-axis diameter was 1 cm or larger. ¶ Vascular invasion Grade 0: normal, with a fat plane or normal pancreas between tumour and vessel; Grade 1: loss of fat plane between tumour and vessel, with or without smooth displacement of the vessel); Grade 2: flattening and/or slight irregularity of one side of the vessel; Grade 3: encased vessel with tumour extending around at least two sides (i.e., two thirds of the perimeter), altering its contour and producing concentric or eccentric lumen narrowing; Grade 4: at least one major occluded vessel. | YES | UNCLEAR | YES |
Zamboni [28] (retrospective evaluation) | 2 gastrointestinal radiologists in consensus (>20 and 4 years of experience) | Same as for initial interpretation | YES | YES | YES | |
Furukawa [29] | MPR | More than 1 diagnostic radiologist in conference | Criteria for unresectablity: 1. Extrapancreatic tumour spread, particularly into the celiac axis and the root of the superior mesenteric artery; 2. Para-aortic massive lymph node involvement [the short axis was greater than 1 cm in diameter or there were clusters of 3 or more smaller nodes (each < 1 cm)] 3. Presence of distant metastases and ascites; 4. Portal vein invasion (>90% direct contact). | NO | YES | YES |
Klauss [30] | Curved MPR | 2 radiologists in consensus (with 11 and 23 years of experience) | Not defined for resectability (only for vascular invasion) | NO | YES | NO |
Shah [31] | Not available | Interpretated by an experienced multidisciplinary team | Criteria for unresectablity: 1. Extra-pancreatic disease such as liver, omental, or peritoneal metastases; 2. Bulky (>2 cm) celiac adenopathy; 3. Malignant ascites; 4. Loss of a patent portosplenic confluence, or 360° encasement of the portal or superior mesenteric veins, or 5. Any contact between the tumour and the hepatic artery or superior mesenteric artery. | NO | UNCLEAR | YES |
Manak [32] | MPR | 2 radiologists in consensus | Criteria for unresectability 1. Vascular involvement ¶ 2. Liver and peritoneal metastases 3. Distant lymph nodes metastases. Enlarged lymph nodes (>10 mm) were considered as metastatic. Distant lymph nodes metastases beyond the peripancreatic chains indicated unresectability ¶ Arterial invasion (celiac trunk, superior mesenteric artery and common hepatic artery) was defined as any direct contiguity tumour to artery with complete obliteration of a fat plane even if the contiguity was less than 50%. ¶ Venous invasion (superior mesenteric vein, splenic vein, and portal vein) was defined when the tumour showed contiguity to more than 50% of vein circumference. | NO | YES | YES |
Park [33] | Not defined | 2 abdominal radiologists independently (8 and 7 years CT and MRI experience) | Criteria for unresectability: 1. Distant metastasis: liver, peritoneum, para-aortic lymph nodes, or lung; 2. Invasion into peripancreatic arteries: celiac trunk, hepatic artery, or SMA; 3. Massive venous invasion of portal vein and/or SMV, i.e., tumour infiltration with thrombosis and obliteration of the vessel lumen involving a segment longer than 2 cm; and 4. Infiltration in adjacent organs: stomach, spleen, or colon. | YES | NO | YES |
Satoi [34] | MPR | 1 experienced hepatopancreatolobiliary surgeon and 1 consultant radiologist in consensus | Criteria for potential resectable: 1. Patients with no distant metastases or no tumour extension to a major peripancreatic artery defined as tumour ingrowth with > 50% vessel contiguity in the celiac trunk, common or proper hepatic artery, or superior mesenteric artery 2. Patients with tumours invading the portal vein but in the absence of extended obstruction of the portal vein to distal branches of the superior mesenteric vein 3. Patients with cancer in pancreatic body and tail with celiac trunk invasion and without SMA invasion | NO | UNCLEAR | YES |
Croome [35] | Not available | Not available | Not available | NO | UNCLEAR | NO |
Grieser [36] | MPR and curved MPR and MIP and VR and additional 3D | 2 experienced radiologists independently (4 and 6 years of experience in abdominal MDCT) | Criteria for unresectability: 1. Arterial infiltration (celiac trunk, superior mesenteric artery, common hepatic artery), 2. Distant metastases, and 3. Peritoneal carcinomatosis 4. Additional criterion comprised non-manageable venous infiltration or thrombosis (portal vein, superior mesenteric vein). | YES | YES | YES |
Grossjohann [37] | Not available | Not available | Criteria for resectability: 1. No invasion into larger surrounding vessels or surrounding organs; 2. Not included in a resected Whipple’s specimen; 3. No detection of liver metastases 4. No distant lymph node metastases 5. No peritoneal seeding. | NO | UNCLEAR | YES |
Kaneko [38] | MPR | Experienced radiologists specializing in gastrointestinal radiology | Criteria for unresectability: 1. distant metastases to liver, peritoneum, omentum, or adjacent organs; 2. Invasion of a major peripancreatic vessel (celiac artery, hepatic artery, portal vein, and superior mesenteric artery and vein (Lu grade of 3 or greater) ¶ 3. Venous invasion causing thrombosis of the vein. ¶ Vascular involvement according to Lu 2: Grade 0: tumour not contiguous with vessel; Grade 1: tumour contiguous with less than a quarter of vessel circumference; Grade 2: between a quarter and one half; Grade 3: between one half and three quarters; Grade 4: greater than three quarters or with any evidence of focal vessel narrowing regardless of degree of contiguity. | NO | UNCLEAR | YES |
Lee [39] | MPR and MIP and VR | 2 radiologists independently (completed fellowship in gastrointestinal radiology) | Criteria for unresectability: 1. Extrapancreatic invasion of the adjacent tissues or organs other than the duodenum and spleen, 2. Peritoneal metastasis, 3. Distant metastases, 4. Vascular invasion ¶. ¶ We used the criteria for arterial invasion constituted encasement, vessel margin irregularity, or tumour incursion into the periarterial fat plane with the tumour lying in juxtaposition to the vessel. ¶ Venous invasion was considered present when the tumour caused venous occlusion, flattening or narrowing, apposition with concavity toward the vessel lumen, or a circumferential apposition greater than 180°. | YES | YES | YES |
Koelblinger [40] | MPR and curved MPR | 2 gastrointestinal radiologists independently (>10 years of experience in abdominal CT and MR imaging) | Criteria for unresectablity: 1. Vascular invasion: the main portal vein, the portal venous confluence, the superior mesenteric artery and vein, the celiac trunk, and the hepatic artery, Grade 3 or more ¶; 2. The presence of liver metastases, 3. Peritoneal carcinomatosis, 4. Adjacent organ infiltration, and 5. Pathologic lymph nodes ¶ Vascular invasion according to Li 3
Grade 0: no tumour contiguity; Grade 1: tumour contiguous with less than 90° vessel circumference; Grade 2: tumour contiguous between 90° and 180° circumference; Grade 3: tumour contiguous between 180° and 270° circumference; Grade 4: tumour contiguous with more than 270° circumference. | YES | YES | YES |
Fang [41] | VR | 2 radiologists for CTA 2 radiologists for 3D reconstructions | CTA criteria for unresectablity: 1. A tumour intricately associated with the celiac trunk and its main branches, the abdominal aorta, the inferior vena cava, the portal vein, the superior mesenteric artery, the inferior mesenteric vein such that there is no apparent space in between them; 2. A low-density tumour completely surrounding its neighbouring blood vessels without causing lumen changes; 3. A low-density tumour that causes occlusion or stenosis by vascular invasion. 3D Criteria for unresectability: The following vessels were evaluated: portal vein, superior mesentery artery, inferior vena cava, superior mesenteric vein, left renal vein, right renal vein, hepatic artery, celiac trunk, and abdominal aorta. Type IV and V were classified as unresectable Type IV: the primary tumour was attached to and compressed the large vessels and the vessels had a “moth-eaten” instead of smooth appearance. Type V: the large blood vessels were surrounded by the primary tumour, distortion of the large vessels was evident and significant dilatation of the small pancreatic vein could be observed. | NO | YES | YES |
Khattab [42] | Curved MPR | 2 radiologists in consensus | Criteria of unresectability: 1. Tumours which were larger than 2 cm in size (tumours less than 2 cm may be associated with favorable outcome 2. Presence of local metastasis (such as enlarged lymph nodes outside peripancreatic draining chains) or direct invasion of the surrounding organs with exclusion of the duodenum, or more, 3. Distant metastases (liver or pulmonary metastasis), 4. Infiltration of the walls of major vessels including (celiac trunk, hepatic artery, splenic artery, superior mesenteric artery and portal vein or the superior mesenteric vein) ¶ ¶ Arterial vascular involvement was estimated using the criteria by Lu et al 2. Grade 0–2 was considered operable, whereas grades 3 and 4 were considered radiologically inoperable. Grade 0: no contiguity of tumour to vessel; Grade 1: tumour contiguous less than one quarter of circumference; Grade 2: between one quarter and one half; Grade 3: between one half and three quarters; Grade 4: greater than three quarters. ¶ Venous invasion was defined as tumour-to-vessel circumferential contiguity of 50% or more. Tumour-to-vein circumferential contiguity of less than 50% was not considered venous invasion | NO | YES | YES |
Yao [43] | Not available | Not available | Criteria for resectability: 1. No distant metastases; 2. Absence of tumour-induced occlusion of any aspect of the superior mesenteric-portal vein confluence; 3. Absence of tumour extension to the celiac axis, common hepatic artery and superior mesenteric artery. | NO | UNCLEAR | YES |
Cieslak [44] | Not available | 2 (1 surgeon and 1 expert radiologist) in consensus | Criteria for unresectability: 1. Vascular invasion: when exceeding 270 o of the circumference of the portal vein/superior mesenteric vein or exceeding 90 o of the circumference of the superior mesentery artery, celiac trunk, or hepatic artery; 2. Distant metastases | NO | YES | YES |
Hassanen [45] | Not available | 2 radiologist | Not available | NO | UNCLEAR | NO |
Iscanli [46] | MPR and curved MPR MIP and VR | By one of two radiologists (5 and 12 years of experience in reading pancreatic imaging) | Criteria for unresectability: 1. Distant metastases to the liver, peritoneum, or omentum; 2. Direct invasion of the adjacent organs (except the duodenum); 3. Vascular invasion of a major peripancreatic vessel, according to Lu. A Lu grade 0 to 2 was considered operable, whereas grade 3 and above were radiologically inoperable. A degree of contact of the vessel with the tumour of 180° was considered indeterminate¶. ¶ Lu criteria 2 evaluate vascular involvement by the degree of contact of the vessel with the tumour: Grade 0: no contiguity of tumour to vessels; Grade 1: tumour contiguous less than one quarter (<90°) of vessel circumference; Grade 2: tumour contiguous between one quarter and one half (90°-180°); Grade 3: between one half and three quarters (180°-270°); Grade 4: greater than three quarters (>270°) or any evidence of focal vessel narrowing or irregularity on the vessel wall, regardless of degree of contiguity. | YES | UNCLEAR | YES |
Reference standard and time interval between CT and reference standard
Data on resectability
Study author | Resectable according to CT | Unresectable according to CT | PPV | FP distributions | ||
---|---|---|---|---|---|---|
Resectable according to reference standard (TP) | Unresectable according to reference standard (FP) | Resectable according to reference standard (FN) | Unresectable according to reference standard (TN) | TP/(TP + FP) | ||
Ellsmere [18] | 22 | 14 | 1 | 7 | 61.1% (22/36) | Not available |
Imbriaco [19] (Obs1) | 8 | 2 | 1 | 29 | 80.0% (8/10) | Not available |
Imbriaco [19] (Obs 2) | 7 | 3 | 2 | 28 | 70.0% (7/10) | Not available |
Karmazanovsky [20] (Potential resectable as resectable) | 52 | 18 | 4 | 15 | 74.3% (52/70) | Liver metastases (18) |
Li [21] | 16 | 6 | 1 | 31 | 72.7% (16/22) | Invaded vessels (4)/Liver metastases (1) Peritoneal metastases (1) |
Phoa [22] | 26 | 10 | 15 | 20 | 72.2% (26/36) | Not available |
Imbriaco [23] (Obs 1) | 6 | 2 | 1 | 37 | 75.0% (6/8) | Not available |
Imbriaco [23] (Obs 2) | 6 | 3 | 1 | 36 | 66.7% (6/9) | Not available |
Tamm [24] (Obs 1) | 10 | 2 | 1 | 42 | 83.3% (10/12) | Liver metastases (1)/Peritoneal metastases (1) |
Tamm [24] (Obs 2) | 10 | 3 | 1 | 41 | 76.9% (10/13) | Liver metastases (1)/Peritoneal metastases (1)/Vascular invasion (1) |
Tamm [24] (Obs 3) | 10 | 6 | 1 | 38 | 62.5% (10/16) | Liver metastases (3)/Peritoneal metastases (1)/Vascular invasion (1)/Lung metastases (1) |
Kala [25] | 14 | 14 | 2 | 19 | 50.0% (14/28) | Not available |
Olivie [26] | 23 | 0 | 0 | 5 (palliative procedure) | 100.0% (23/23) | Not applicable |
Smith [27] (Equivocal as resectable) | 10 | 14 | 1 | 8 | 41.7% (10/24) | Vascular invasion (9)/Infiltration beyond pancreas (3)/Liver metastases (1)/Other metastases (1) |
Smith [27] (Equivocal as unresectable) | 9 | 7 | 2 | 15 | 56.3% (9/16) | Vascular invasion (3)/Infiltration beyond pancreas (3)/Other metastases (1) |
Zamboni [28] (Clinical evaluation) | 78 | 10 | 0 | 26 | 88.6% (78/88) | Vascular invasion (1)/Liver metastases (5) Lymph nodes (2)/Peritoneal metastases (2) |
Zamboni [28] (Retrospective evaluation) | 78 | 2 | 0 | 34 | 97.5% (78/80) | Not available |
Furukawa [29] (Probably unresectable as unresectable) | 68 | 11 | 0 | 134 | 86.1% (68/79) | Peritoneal metastases (7)/Liver (3)/LN (1) |
Klauss [30] | 21 | 0 | 1 | 6 | 100% (21/21) | NA |
Shah [31] | 34 | 13 | NA | NA | 72.3% (34/47) | Metastases (9)/R2 resection (1)/Locally advanced (3) |
Manak [32] | 44 | 4 | NA | NA | 91.7% (44/48) | Vascular invasion (1)/Liver metastases (2)/Peritoneal metastases and lymph nodes (1) |
Park [33] (Obs 1) | 35 | 3 | 7 | 9 | 92.1% (35/38) | Not available |
Park [33] (Obs 2) | 35 | 4 | 7 | 8 | 89.7% (35/39) | Not available |
Satoi [34] | 29 | 3 | NA | NA | 90.6% (29/32) | Distant metastases (3) |
Croome [35] | 24 | 16 | NA | NA | 60.0% (24/40) | Liver metastases (3)/Peritoneal metastases (1)/Omental seeding (1)/Vascular invasion (10)/Vascular invasion and lymph nodes (1) |
Grieser) [36] (Without 3D) (Obs 1) | 32 | 6 | 1 | 31 | 84.2% (32/38) | Not available |
Grieser [36] (With 3D) (Obs 1) | 32 | 4 | 1 | 33 | 88.9% (32/36) | Not available |
Grieser [36] (Without 3D) (Obs 2) | 32 | 5 | 1 | 32 | 86.5% (32/37) | Not available |
Grieser [36] (With 3D) (Obs 2) | 32 | 3 | 1 | 34 | 91.4% (32/35) | Not available |
Grossjohann [37] | 10 | 9 | 2 | 8 | 53% (10/19) | Liver metastases (3)/Lymph node metastases (1)/Vascular invasion (5) |
Kaneko [38] (Equivocal as resectable) | 67 | 20 | 0 | 22 | 77.1% (67/87) | Liver metastases (4)/Vascular invasion (10)/Peritoneal metastases (6) |
Kaneko [38] (Equivocal as unresectable) | 67 | 12 | 0 | 30 | 84.8% (67/79) | Liver metastases (4)/Vascular invasion (4)/Peritoneal metastases (4) |
Lee [39] (Obs 1) | 35 | 6 | 4 | 11 | 85.4% (35/41) | Peritoneal metastases (2)/Liver metastases (1)/Vascular invasion (1)/Adjacent organs (2) |
Lee [39] (Obs 2) | 35 | 7 | 4 | 10 | 83.3% (35/42) | Not available |
Koelblinger [40] (Obs 1) | 13 | 2 | 2 | 6 | 86.7% 13/15 | Carcinomatosis (1)/Lymph node (1) |
Koelblinger [40] (Obs 2) | 13 | 3 | 2 | 5 | 81.3% 13/16 | Carcinomatosis (2)/Lymph node (1) |
Fang [41] CTA | 30 | 2 | 8 | 17 | 93.8% (30/32) | Vascular invasion (2) |
Fang [41] 3D | 38 | 0 | 0 | 19 | 100% (38/38) | Not Applicable |
Khattab [42] | 15 | 3 | NA | NA | 83.3% (15/18) | Vascular invasion (2)/Liver and lymph nodes (1) |
Yao [43] | 25 | 11 | NA | NA | 69.4% (25/36) | Bone metastases (2)/Lymph nodes (1)/Liver metastases (8) |
Cieslak [44] | 75 | 8 | 1 | 2 | 90.4% (75/83) | Distant metastasis (4)/Locally advanced (3)/Liver metastases (1) |
Hassanen [45] | 13 | 6 | 2 | 26 | 68.4% (13/19) | Vascular invasion (4)/Liver metastases (2) |
Iscanli [46] (Equivocal as resectable) | 62 | 21 | 0 | 41 | 75.7% (62/83) | Liver metastases (9)/Peritoneal metastases (3)/Vascular invasion (9) |
Iscanli [46] (Equivocal as unresectable) | 62 | 17 | 0 | 44 | 78.5% (62/79) | Liver metastases (9)/Peritoneal metastases (3)/Vascular invasion (5) |